The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01818505

Acronym

URIC

Enrollment

210

Registered

2013-03-26

Start date

2013-03-31

Completion date

Unknown

Last updated

2014-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphospholipid Syndrome, Endothelial Dysfunction, Gout, Hyperuricemia, Metabolic Syndrome

Keywords

antiphospholipid syndrome, gouty arthritis, Hyperuricemia, metabolic syndrome, osteoarthritis, cardiovascular co-morbidities

Brief summary

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

Detailed description

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, we'll analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. We expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities. Patient eligibility： 1. Patients with gout 2. Patients with asymptomatic hyperuricemia 3. Patients of osteoarthritis but without hyperuricemia and gout Exclusion Criteria： Patients younger than 20 years old

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient with gouty arthritis 2. Patient with asymptomatic hyperurecemia 3. Patient of osteoarthritis but without hyperuricemia and gout

Exclusion criteria

1.Patient younger than 20 y/o.

Design outcomes

Primary

Measure	Time frame
development of metabolic syndrome or cardiovascular events	36 months

Secondary

Measure	Time frame
Acute myocardial infarct or stroke	36 months or more

Countries

Taiwan

Contacts

Primary ContactYu-Min Kuo, M.D.

543goole@gmail.com886972655701

Outcome results